New migraine nasal spray enters first human safety trial

NCT ID NCT07016516

Completed Symptom relief Sponsor: Sichuan Purity Pharmaceutical Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tested a new nasal spray called PRT-064040 in 80 healthy Chinese adults to see if it is safe and how the body processes it. Participants received either a single dose or seven daily doses of the spray or a placebo. The study does not yet test if the spray helps migraines, but it is a first step toward a potential new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PRT-064040 nasal spray
What this could lead to: If this early study shows the drug is safe, it could lead to a new nasal spray option for treating migraine attacks.
What could go wrong: This is a very early Phase 1 trial in healthy people, not migraine patients. It only tests safety and how the drug moves through the body, not whether it actually works for migraines.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIGRAINE

Contacts and locations

Locations

The Third Hospital of Changsha

Changsha, Hunan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.